Why Tango Therapeutics, Inc.’s (TNGX) Stock Is Down 5.61%
As of Tuesday, November 17, Tango Therapeutics, Inc.’s TNGX share price has dipped by 5.61%, which has investors questioning if this is right time to buy.Jenna Brashear
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
Jenna Brashear
Michael Rose
Rosalio Madrigal
Rosalio Madrigal
Michael Rose
| Share Statistics | TNGX | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $3,709.4 | $213.9 | 64% |
|
| Shares Out (Mil) | 173.9 | 55.4 | 73% |
|
| Institutional Ownership | 99.1% | 93.3% | 84% |
|
| Float (Mil) | 143.1 | 40.6 | 67% |
|
| Beta | 1.22 | 0.98 | 71% |
|
| Avg Daily Volume (000s) | 2,904 | 597 | 85% |
|
| Price Change (52-week) |
174.3% | 40.9% | 98% |
|
| Growth | TNGX | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 52.0% | 13.2% | 96% |
|
| Net Income (5yr) | (14.3%) | (10.7%) | 26% |
|
| EPS (5yr) | 11.7% | 15.5% | 50 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | 16.8% | (15.7%) | 76% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 13 | 13 | 13 | |
| Current EPS | ($0.419) | ($1.472) | ($1.793) | |
| Month Ago EPS | ($0.373) | ($1.397) | ($1.661) | |
| # Rev Up | 0 | 1 | 0 | |
| # Rev Down | 1 | 1 | 1 | |
| Three Months Ago EPS | ($0.367) | ($1.380) | ($1.628) | |
| Year/Year Chg | 6.6% | 68.2% | 137.5% | |
| Financials | TNGX | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $39 | na |
|
| Net Income (TTM) (Mil) | ($208) | ($44) | 6% |
|
| EPS (TTM) | ($1.378) | ($1.400) | 17% |
|
| Operating Cash Flow (TTM) (Mil) | ($150) | ($34) | 5% |
|
| Net Cash Flow (TTM) (Mil) | $28 | $-0 | 66% |
|
| Long-Term Debt (Q1) (Mil) | $28 | $4 | 34% |
|
| Enterprise Value (Q1) (Mil) | $2,907 | $135 | 54% |
|
| Valuation | TNGX | Industry Median |
Percentile (All Stocks) |
|
| P/B | 3.78 | 1.97 | 75% |
|
| P/E | na | 17.6 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 0.8 | na |
|
| Ratios | TNGX | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 67.9% | na |
|
| Net Margin | na | (50.8%) | na |
|
| ROA | (33.5%) | (47.5%) | 15% |
|
| ROE | (36.5%) | (51.9%) | 18% |
|
| Liabilities to Assets | 5.2% | 29.7% | 2% |
|
| F-Score | 3 | 3 | 18% |
|
Tango Therapeutics, Inc. did not pass any screens on 11/18/2026.
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors